Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Novartis : Lupin receives FDA approval for generic TOBI inhalation solution

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/23/2017 | 09:52pm CET

Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Tobramycin Inhalation Solution USP, 300 mg/5 ml from the United States Food and Drug Administration (FDA) to market a generic version of Novartis Pharmaceuticals Corporation's TOBI 300 mg/5 ml. Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Tobramycin Inhalation Solution USP, 300 mg/5 ml from the United States Food and Drug Administration (FDA) to market a generic version of Novartis Pharmaceuticals Corporation's TOBI 300 mg/5 ml.

Lupin's Tobramycin Inhalation Solution USP, 300 mg/5 ml is the AN rated generic equivalent of Novartis Pharmaceuticals Corporation's TOBI 300 mg/5 ml. It is indicated for the management of cystic fibrosis patients with P. aeruginosa.

Tobramycin Inhalation Solution USP, 300 mg/5 ml had US sales of USD 133.6 million (IMS MAT December 2016).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

(c) 2017India Infoline Ltd. All rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS AG
09:52p NOVARTIS : Lupin receives FDA approval for generic TOBI inhalation solution
06:44p NOVARTIS : Global Alprazolam Market 2017 - Endo, Mylan, Sandoz, Actavis, Apotex
06:21p NOVARTIS : Kisqali® ribociclib, LEE011 receives FDA approval as first-line treat..
03:59p OTSUKA : Ribociclib (LEE011) Receives Regulatory Approval in U.S. as a First-Lin..
03:20p NOVARTIS : Serelaxin Setback Puts Focus On Entresto
07:16a NOVARTIS : Alcon receives US FDA approval for new AcrySof® IQ ReSTOR® +2.5 Multi..
03/22 Global Inhalation & Nasal Spray Generic Drugs Market- Teva, Allergan PLC, Cip..
03/22 NOVARTIS` : Cosentyx is first and only IL-17A inhibitor to potentially modify th..
03/22 NOVARTIS : provides update on Phase III study of RLX030 (serelaxin) in patients ..
03/21 IMS HEALTH : Glenmark gets tentative nod from USFDA for Fingolimod capsules
More news
Sector news : Pharmaceuticals - NEC
10:46pDJPRESS RELEASE : FDA Grants Approval for -3-
10:46pDJPRESS RELEASE : FDA Grants Approval for -2-
10:46pDJPRESS RELEASE : FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immuno..
09:32p SEC charges two Israeli residents with Mobileye insider trading
11:53a TEVA PHARMACEUTICAL INDUSTRIES : Pharm says media reports of up to 6,000 layoffs..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
04:13p Discussing The Evolving AML Landscape With A Key Opinion Leader
02:23p Pharma Development Budgets Grow As Roche Remains A Believer
03/22 Serelaxin Setback Puts Focus On Entresto
03/22 BIOLINERX : Update And Preview Of The Company's Q4 And FY 2016 Financial Results..
03/22 Novartis' serelaxin flunks late-state heart failure study; shares ease a frac..
Advertisement
Financials ($)
Sales 2017 48 429 M
EBIT 2017 11 388 M
Net income 2017 7 506 M
Debt 2017 15 034 M
Yield 2017 3,81%
P/E ratio 2017 22,47
P/E ratio 2018 19,82
EV / Sales 2017 4,32x
EV / Sales 2018 4,11x
Capitalization 194 072 M
More Financials
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 32
Average target price 80,4 $
Spread / Average Target 8,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG0.47%194 072
JOHNSON & JOHNSON9.59%342 277
ROCHE HOLDING LTD.7.52%217 164
PFIZER INC.6.13%205 273
MERCK & CO., INC.7.86%174 344
SANOFI7.63%115 490
More Results